Compare · IXHL vs NVO
IXHL vs NVO
Side-by-side comparison of Incannex Healthcare Inc. (IXHL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IXHL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 5874.7x IXHL ($37.9M).
- Over the past year, IXHL is down 87.0% and NVO is down 22.5% - NVO leads by 64.4 points.
- NVO has hit the wire 4 times in the past 4 weeks while IXHL has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 1 for IXHL).
- Company
- Incannex Healthcare Inc.
- Novo Nordisk A/S
- Price
- $3.20+2.56%
- $50.31-2.25%
- Market cap
- $37.9M
- $222.81B
- 1M return
- -14.44%
- +15.47%
- 1Y return
- -86.97%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 1
- 25
Incannex Healthcare Inc.
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IXHL
- Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
- Incannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
- Incannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Incannex Announces Initiation of Research Coverage by Alliance Global Partners
- Incannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Alliance Global Partners initiated coverage on Incannex Healthcare with a new price target
- SEC Form 10-Q filed by Incannex Healthcare Inc.
- Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
- Incannex Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S